Attorney Advertising — Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Biogen, Inc. (“Biogen” or the “Company”) (NasdaqGS:BIIB -News). Such investors are advised to contact Peretz Bronstein or his investor relations coordinator Eitan Kimelman email@example.com or 212-697-6484.
The investigation concerns whether Biogen and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
On July 24, 2015, pre-market, Biogen reported Q2 2015 results and updated its full-year financial guidance from 14-16% to 6-8% above 2014 revenues. The Company also announced that sales of the company’s multiple-sclerosis drug tecfidera have slowed on safety concerns following last year’s report of the death of a tecfidera patient.
On this news, Biogen shares have dropped as much as $74.34, or 19.31%, during intraday trading on July 24, 2015.
If you are aware of any facts relating to this investigation, or purchased shares of Biogen, you can assist this investigation by contacting Peretz Bronstein or his Investor Relations Coordinator Eitan Kimelman of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via firstname.lastname@example.org. Those who inquire by e-mail are encouraged to include their mailing address, email and telephone number.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Eitan Kimelman 212-697-6484